Company Info
Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for rare pediatric diseases. Established in 2007, Fennec has dedicated itself to advancing therapies that address unmet medical needs, particularly in the area of pediatric healthcare. The company's flagship product, Saphnelo (sodium thiosulfate), has been designed to offer a new solution for patients suffering from specific conditions. Fennec Pharmaceuticals is headquartered in Durham, North Carolina, but its roots and operations extend across various regions, including Canada. The company is publicly traded on the Toronto Stock Exchange (TSE) under the ticker symbol "FRX." Fennec's commitment to research and development has positioned it as a leader in its field, focusing on bringing critical therapies to market for children and their families. By addressing the gaps in treatment options, Fennec strives to make a meaningful difference in the lives of patients worldwide.